drugset / Trial / NCT03890731
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.
Timeline
- Start
- 2019-04-02
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 60 mg | Oral |
| Subject | Regorafenib | Small molecule | 80 mg | Oral |
| Subject | Regorafenib | Small molecule | 120 mg | Oral |
| Subject | Regorafenib | Small molecule | 160 mg | Oral |